Arcus Biosciences, Inc.

For the period ended Jun 30, 2026. Filed Aug 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 5, 2026

RCUS$18.67-1.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(In millions, except per share amounts)

	Three Months EndedJune 30,		Six Months EndedJune 30,
	2026	2025	2026	2025
Revenues:
License and development services (Includes $8, $152, $18 and $172 from a related party)	$16	$152	$28	$172
Other collaboration(Includes $25, $8, $30 and $16 from a related party)	25	8	30	16
Total revenues	41	160	58	188
Operating expenses:
Research and development (Includes $2, $11, $2 and $6 from a related party)	113	139	235	261
General and administrative(Includes $—, $2, $— and $2 from a related party)	24	29	53	57
Total operating expenses	137	168	288	318
Loss from operations	(96)	(8)	(230)	(130)
Non-operating income (expense):
Interest and other income, net	8	10	17	21
Interest expense	(3)	(2)	(6)	(3)
Total non-operating income, net	5	8	11	18
Income (loss) before income taxes	(91)	—	(219)	(112)
Income tax expense	—	—	—	—
Net income (loss)	$(91)	$—	$(219)	$(112)
Net income (loss) per share:
Basic	$(0.72)	$—	$(1.74)	$(1.09)
Diluted	$(0.72)	$—	$(1.74)	$(1.09)
Shares used to compute net income (loss) per share:
Basic	126.1	106.1	125.7	102.3
Diluted	126.1	106.5	125.7	102.3

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.